[Form 4] Inhibikase Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing – Inhibikase Therapeutics, Inc. (IKT)

On 06/30/2025, director Dennis N. Berman received 108,176 stock options with an exercise price of $1.95 per share. The grant vests on the earlier of 06/30/2026 or the day prior to the company’s next annual shareholder meeting, subject to continued board service, and expires on 06/30/2032. No common shares were bought or sold in this filing; the reporting person’s beneficial ownership now includes the newly issued options, held directly.

Insights

Securities Analyst

TL;DR: Routine option grant to director; negligible market impact.

The filing discloses a standard equity compensation grant—108,176 options at $1.95—awarded to director Dennis Berman. No cash was exchanged and no common shares were traded. Such grants are customary for smaller biotech boards to align governance incentives without affecting cash burn. Given IKT’s modest market capitalization, the option amount is <1% of shares outstanding, so dilution risk is immaterial. Investors should view this as routine housekeeping rather than a signal of fundamental change.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BERMAN DENNIS N

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.95	06/30/2025		A		108,176		(1)	06/30/2032	Common Stock	108,176	$0	108,176	D

Explanation of Responses:

1. The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ David McIntyre, attorney-in-fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did IKT grant to director Dennis Berman on 06/30/2025?

108,176 options with a $1.95 exercise price were granted.

When do the newly granted IKT options vest?

They vest on the earlier of 06/30/2026 or the day before the next annual shareholder meeting.

Did the Form 4 report any purchase or sale of IKT common shares?

No. The filing only reports an option grant; no shares were bought or sold.

What is the expiration date of the IKT director’s options?

The options expire on 06/30/2032.

Does this Form 4 filing materially impact IKT shareholders?

The option grant is routine and represents a negligible dilution; it is not considered materially impactful.